CCR2 Inhibition Reduces Tumor‐Associated Myeloid‐Derived Suppressor Cells and Unmasks an α‐PD‐1 Effect to Slow Tumor Progression in Checkpoint Inhibitor Resistant Gliomas

INTRODUCTION Immuno-therapy directed at the PD-1/PD-L1 axis has yielded significant treatment advances in various human cancers. However, these outcomes have not extended to glioblastoma (GBM), wit...